Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.23 USD | +8.39% | +3.53% | -16.75% |
04-18 | Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board | CI |
03-12 | Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024 | CI |
Business Summary
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Amit Kumar
CEO | Chief Executive Officer | 59 | 12-10-31 |
Michael Catelani
DFI | Director of Finance/CFO | 57 | 16-10-31 |
Pamela Garzone
PRN | Corporate Officer/Principal | 69 | 21-09-06 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Lewis Titterton
BRD | Director/Board Member | 79 | 99-06-30 |
Amit Kumar
CEO | Chief Executive Officer | 59 | 12-10-31 |
Emily Gottschalk
BRD | Director/Board Member | 63 | 19-10-22 |
Arnold Baskies
BRD | Director/Board Member | 74 | 16-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 31,899,800 | 30,335,901 ( 95.10 %) | 0 | 95.10 % |
Company contact information
Anixa Biosciences, Inc.
3150 Almaden Expressway Suite 250
95118, San Jose
+408 708 9808
http://www.anixa.comSector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.75% | 103M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ANIX Stock
- Company Anixa Biosciences, Inc.